StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SHREEGANES.BO$0.61+1.67%
Fair $0.61+0.0%

SHREEGANES.BO

Shree Ganesh Bio-Tech (India) Limited

Basic Materials / Agricultural InputsBSE

$0.61

+0.01 (+1.67%)

Fairly Valued+0.0%Fair Value $0.61Fund rank 20/100 · Data gapFallback financials|
SA 19/F
F-Score: 2/9
Margin CompressionLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 14%

FCF escenarios

weak_data · normalized FCF $-82.0M · quality 27.7/100

Data gap 20/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 3/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

19/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. Operating margin has declined for 3 consecutive years ROE is 0.6%, below the 5% threshold
Thesis & Journal · SHREEGANES.BOLocal privado en este navegador · Shree Ganesh Bio-Tech (India) Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$243M

P/E

61.0x

↑

EV/EBITDA

47.2x

↑

ROE

0.6%

↑

Gross Margin

-1.7%

↓

Debt/Equity

N/A

•
52-Week Range$1
$1$1

TradingView lightweight chart

SHREEGANES.BO price, volumen y niveles de valoración

Último $0.610Periodo -84.8%
Fair value: $0.610

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

-57.0%

FCF CAGR

—

FCF margin

-164.9%

FCF / Net income

-21.70x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $49.7M · net income $3.8M · FCF $-82.0M

2023-FY → 2026-FY

Gross margin

-1.7%-6.2% pts

Operating margin

-19.3%-22.7% pts

Net margin

7.6%+4.3% pts

FCF margin

-164.9%-181.8% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$49.7M$49.7M$229.6M$202.8M$624.5M
Net Income$3.8M$3.8M$2.8M$6.2M$20.4M
EBITDA$5.1M$5.1M$3.9M$8.6M$27.1M
EPS——0.010.020.05
Gross Margin-1.7%-1.7%1.4%1.2%4.5%
Operating Margin-19.3%-19.3%-4.6%-1.0%3.4%
Net Margin7.6%7.6%1.2%3.1%3.3%
Balance Sheet
Current Ratio70.2270.22———
Cash Flow
Free Cash Flow$-82.0M$-82.0M$-102.1M$101.6M$105.4M
Returns
ROE0.6%0.6%0.4%1.0%3.3%
Valuation
P/E61.0061.0094.0067.0025.20
EV/EBITDA47.2347.2396.6961.9418.32
P/B0.380.380.590.850.81
Growth & Yield
Revenue Growth-78.3%-78.3%13.2%-67.5%—
EPS Growth——-50.0%-60.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -31.5%

Total return

-31.5%

Start / end P/E

n/dx → n/dx

EPS bridge

0.01 → n/d

Residual

-31.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-31.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.